My Pancreatic Cancer came back — what are my options now

Your Pancreatic Cancer Recurrence: Understanding Your Options

I'm sorry you're facing a recurrence. This is a challenging situation, but there are more treatment options available now than ever before. Let me help you understand what's typically considered and what questions to ask your team.

STEP 1: HOW DOCTORS APPROACH RECURRENCE

When pancreatic cancer returns, your oncology team evaluates several key factors:

Location and extent of recurrence:

• Where did it come back? (same area, distant sites, or both?)
• How many spots are there?
• Can it be surgically removed?

Your overall health:

• Your performance status (ability to handle treatment)
• Other medical conditions
• How you tolerated previous treatments

Tumor characteristics:

• Has your tumor been molecularly profiled (genetic testing)?
• What mutations does it have?
• How did it respond to your first treatment?

According to NCCN Guidelines for Pancreatic Cancer, the decision-making process considers whether the recurrence is localized (in one area) or metastatic (spread to distant organs), as this dramatically changes treatment options.

---

STEP 2: GENERAL TREATMENT APPROACHES THAT EXIST

A) Genetic/Molecular Testing (If Not Already Done)

This is your most important first step. According to Dr. [removed] O'Reilly's 2024 expert guidance on pancreatic cancer, you should have:

• Tumor molecular profiling (testing your cancer cells for mutations)
• Germline testing (checking if you carry inherited cancer genes)

Why this matters: About 15-20% of pancreatic cancers have actionable mutations that open specific treatment doors:

• BRCA1/BRCA2 or PALB2 mutations → PARP inhibitors + chemotherapy combinations
• KRAS mutations (found in ~90% of pancreatic cancers) → Emerging KRAS-targeted drugs
• Mismatch repair deficiency (dMMR) → Immunotherapy options
• MTAP deletion (15-20% of cases) → Emerging targeted therapies

---

B) Chemotherapy Options

Standard approaches for recurrent disease:

• FOLFIRINOX - A combination of 4 chemotherapy drugs (fluorouracil, leucovorin, irinotecan, oxaliplatin). This is often used for first-line treatment and can be re-used if you had a good response initially and time has passed.

• Gemcitabine + Abraxane (nab-paclitaxel) - Another combination option, especially if FOLFIRINOX was your previous treatment

• Single-agent chemotherapy - If your health status has changed or you need a gentler approach

According to Let's Win Pancreatic Cancer resources, patients who received neoadjuvant (pre-surgery) FOLFIRINOX followed by surgery and adjuvant (post-surgery) chemotherapy showed improved survival outcomes, suggesting chemotherapy combinations remain important tools.

---

C) Targeted Therapy (Based on Your Tumor's Mutations)

KRAS-targeted drugs:

• New KRAS inhibitors are now FDA-approved or in advanced trials
• Often combined with chemotherapy or immunotherapy for better results
• Dr. [removed] Strickler notes these represent a major breakthrough after decades of research

PARP Inhibitors:

• For patients with DNA repair deficiencies (BRCA1, BRCA2, PALB2 mutations)
• Often combined with immunotherapy
• Example: niraparib (a PARP inhibitor) combined with ipilimumab (immunotherapy)

Emerging targeted approaches:

• MTAP inhibitors (for MTAP-deleted tumors)
• RAS pathway inhibitors
• Other precision medicine approaches

---

D) Immunotherapy

Single-agent immunotherapy:

• Checkpoint inhibitors (like pembrolizumab) for tumors with mismatch repair deficiency
• According to Let's Win Pancreatic Cancer, patients with mismatch repair defects showed remarkable responses, with some achieving complete responses (cancer disappeared)

Combination immunotherapy:

• Combining two immune checkpoint inhibitors
• Immunotherapy + chemotherapy combinations
• Immunotherapy + targeted therapy (especially for BRCA-mutated tumors)

Emerging approaches:

• Personalized neoantigen vaccines (teaching your immune system to recognize your specific cancer)
• CD40 agonists (activating immune cells)
• CD73 inhibitors (removing immune suppression)

---

E) Radiation Therapy

• Stereotactic body radiation therapy (SBRT) - Focused high-dose radiation
• May be combined with immunotherapy for metastatic disease
• Useful for isolated recurrences in specific locations

---

F) Surgery (If Applicable)

• If recurrence is localized and resectable, surgery may be an option
• Requires careful evaluation by a pancreatic cancer surgeon
• Often combined with chemotherapy before and/or after surgery

---

G) Clinical Trials

This is critical for recurrent disease. According to NCCN Guidelines and multiple expert sources, clinical trials should be considered at every stage because:

• They offer access to cutting-edge treatments not yet widely available
• Patients in trials often have better outcomes than those on standard treatment alone
• They may be your best option for extended survival

Types of trials available:

• Combination chemotherapy + immunotherapy trials
• Targeted therapy trials (KRAS inhibitors, PARP inhibitors)
• Vaccine trials
• Novel drug combinations

---

STEP 3: QUESTIONS TO ASK YOUR ONCOLOGY TEAM

These questions will help you understand YOUR specific situation and options:

1. "Has my tumor been molecularly profiled (genetic tested)? Can I see the complete report?"

   • This is essential. The report should list specific mutations and treatment implications.

2. "Based on my tumor's genetics and my previous treatment, what are the 3-4 most appropriate treatment options for me?"

   • Ask them to explain the pros/cons of each approach.

3. "Are there clinical trials I'm eligible for? Can you help me find them, or should I search independently?"

   • Mention resources like ClinicalTrials.gov, Let's Win Trial Finder, Massive Bio, or myTomorrows.

4. "How will we measure if treatment is working?"

   • Ask about CA 19-9 tumor markers, imaging schedules, and what response looks like.

5. "Should I get a second opinion from a pancreatic cancer specialist at an academic medical center?"

   • This is especially important for recurrent disease. Major centers often have access to trials and cutting-edge approaches.

6. "What is my performance status, and how does that affect my treatment options?"

   • Understanding your functional ability helps determine what you can tolerate.

7. "If my first treatment was FOLFIRINOX, can we use it again, or should we try something different?"

   • The answer depends on how long ago you finished, how you responded, and your current health.

8. "Are there targeted therapies or immunotherapies I'm eligible for based on my tumor's mutations?"

   • This is where precision medicine can make a real difference.

---

STEP 4: IMPORTANT CONTEXT FROM PANCREATIC CANCER EXPERTS

From Dr. [removed] O'Reilly (2024 expert guidance):

• "You should get point-of-care genetic testing at your first meeting, accompanied by educational videos to explain results"
• The field is rapidly evolving with new KRAS inhibitors, immunotherapy combinations, and personalized approaches
• About 15-20% of patients have MTAP deletions with emerging treatment implications

From Dr. [removed] Strickler (Duke University):

• Precision medicine is the future of pancreatic cancer treatment
• Genetic testing should guide every treatment decision
• Combination therapies (chemotherapy + immunotherapy + targeted therapy) show more promise than single approaches
• Early detection and aggressive treatment remain critical

From survivor stories in Let's Win Pancreatic Cancer:

• Patients who actively engaged in their care, sought second opinions, and participated in clinical trials often had better outcomes
• Molecular profiling led to clinical trial participation that extended survival
• Combination approaches (surgery + chemotherapy + clinical trials) produced some of the best results

---

CRITICAL NEXT STEPS

1. Get molecular profiling done immediately if not